Eagle Pharmaceuticals (EGRX) Competitors $1.80 +0.15 (+9.09%) As of 03:19 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsSustainabilityTrendsBuy This Stock EGRX vs. MGNX, SAVA, COYA, GNLX, OPTN, CCCC, HLVX, CRBU, CABA, and CRBPShould you be buying Eagle Pharmaceuticals stock or one of its competitors? The main competitors of Eagle Pharmaceuticals include MacroGenics (MGNX), Cassava Sciences (SAVA), Coya Therapeutics (COYA), Genelux (GNLX), OptiNose (OPTN), C4 Therapeutics (CCCC), HilleVax (HLVX), Caribou Biosciences (CRBU), Cabaletta Bio (CABA), and Corbus Pharmaceuticals (CRBP). These companies are all part of the "pharmaceutical products" industry. Eagle Pharmaceuticals vs. MacroGenics Cassava Sciences Coya Therapeutics Genelux OptiNose C4 Therapeutics HilleVax Caribou Biosciences Cabaletta Bio Corbus Pharmaceuticals MacroGenics (NASDAQ:MGNX) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, community ranking, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk. Does the MarketBeat Community prefer MGNX or EGRX? MacroGenics received 15 more outperform votes than Eagle Pharmaceuticals when rated by MarketBeat users. However, 65.50% of users gave Eagle Pharmaceuticals an outperform vote while only 61.88% of users gave MacroGenics an outperform vote. CompanyUnderperformOutperformMacroGenicsOutperform Votes42761.88% Underperform Votes26338.12% Eagle PharmaceuticalsOutperform Votes41265.50% Underperform Votes21734.50% Do analysts prefer MGNX or EGRX? MacroGenics currently has a consensus price target of $6.13, indicating a potential upside of 288.89%. Given MacroGenics' stronger consensus rating and higher possible upside, research analysts clearly believe MacroGenics is more favorable than Eagle Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MacroGenics 0 Sell rating(s) 7 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.40Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders and institutionals have more ownership in MGNX or EGRX? 96.9% of MacroGenics shares are held by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are held by institutional investors. 13.0% of MacroGenics shares are held by company insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media prefer MGNX or EGRX? In the previous week, MacroGenics had 10 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 11 mentions for MacroGenics and 1 mentions for Eagle Pharmaceuticals. MacroGenics' average media sentiment score of 0.17 beat Eagle Pharmaceuticals' score of 0.00 indicating that MacroGenics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MacroGenics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Eagle Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation and earnings, MGNX or EGRX? Eagle Pharmaceuticals has higher revenue and earnings than MacroGenics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMacroGenics$152.43M0.65-$9.06M-$0.89-1.77Eagle Pharmaceuticals$257.55M0.09$35.64MN/AN/A Which has more risk and volatility, MGNX or EGRX? MacroGenics has a beta of 2.2, meaning that its share price is 120% more volatile than the S&P 500. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Is MGNX or EGRX more profitable? Eagle Pharmaceuticals has a net margin of 0.00% compared to MacroGenics' net margin of -69.07%. Eagle Pharmaceuticals' return on equity of 0.00% beat MacroGenics' return on equity.Company Net Margins Return on Equity Return on Assets MacroGenics-69.07% -89.42% -38.57% Eagle Pharmaceuticals N/A N/A N/A SummaryMacroGenics beats Eagle Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Get Eagle Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EGRX vs. The Competition Export to ExcelMetricEagle PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.38M$6.50B$5.34B$8.42BDividend YieldN/A2.64%5.21%4.11%P/E RatioN/A9.1526.8519.72Price / Sales0.09252.36387.23121.26Price / Cash0.4065.8538.2534.62Price / BookN/A6.456.774.51Net Income$35.64M$144.21M$3.23B$248.32M7 Day Performance-7.22%2.38%1.81%0.60%1 Month Performance9.09%4.50%10.93%13.18%1 Year Performance-52.76%-2.75%17.15%7.39% Eagle Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EGRXEagle PharmaceuticalsN/A$1.80+9.1%N/A-62.2%$23.38M$257.55M0.00100Gap UpMGNXMacroGenics3.5559 of 5 stars$1.59+0.6%$6.38+300.9%-65.0%$100.31M$148.34M-1.01430News CoverageAnalyst ForecastAnalyst RevisionSAVACassava Sciences3.8109 of 5 stars$2.07-1.0%$54.50+2,532.9%-90.8%$100.00MN/A-1.5030COYACoya Therapeutics2.0983 of 5 stars$5.97+0.7%$17.00+184.8%-31.7%$99.85M$3.55M-9.186News CoverageAnalyst DowngradeAnalyst RevisionGNLXGenelux1.2209 of 5 stars$2.61+5.2%$17.75+580.1%-50.4%$98.49M$8,000.00-2.7510OPTNOptiNose2.982 of 5 stars$9.71+0.2%$9.00-7.3%-44.4%$98.33M$78.23M-2.31190News CoverageAnalyst ForecastAnalyst RevisionCCCCC4 Therapeutics2.5321 of 5 stars$1.54+11.6%$12.00+679.2%-76.4%$97.99M$39.78M-0.91150Gap DownHLVXHilleVax2.4637 of 5 stars$1.95-1.0%$3.00+53.8%-86.9%$97.78MN/A-0.6320News CoveragePositive NewsCRBUCaribou Biosciences2.7517 of 5 stars$1.05+11.9%$7.40+604.8%-67.2%$97.66M$9.92M-0.64100CABACabaletta Bio2.2808 of 5 stars$1.92-5.4%$20.33+959.0%-85.3%$97.43MN/A-0.8950News CoverageEarnings ReportAnalyst RevisionGap DownCRBPCorbus Pharmaceuticals4.5867 of 5 stars$7.76+5.7%$50.88+555.6%-83.6%$94.96MN/A-1.6540Positive News Related Companies and Tools Related Companies MGNX Alternatives SAVA Alternatives COYA Alternatives GNLX Alternatives OPTN Alternatives CCCC Alternatives HLVX Alternatives CRBU Alternatives CABA Alternatives CRBP Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EGRX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eagle Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eagle Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
